Dusan Stefoski to Double-Blind Method
This is a "connection" page, showing publications Dusan Stefoski has written about Double-Blind Method.
Connection Strength
0.148
-
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2016 Feb; 23(2):412-5.
Score: 0.030
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May; 13(5):472-81.
Score: 0.026
-
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler. 2014 Apr; 20(4):464-70.
Score: 0.026
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75.
Score: 0.025
-
4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology. 1991 Sep; 41(9):1344-8.
Score: 0.022
-
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3):254-60.
Score: 0.019